BR112015029144A2 - formulações de gel para guiar radioterapia - Google Patents

formulações de gel para guiar radioterapia

Info

Publication number
BR112015029144A2
BR112015029144A2 BR112015029144A BR112015029144A BR112015029144A2 BR 112015029144 A2 BR112015029144 A2 BR 112015029144A2 BR 112015029144 A BR112015029144 A BR 112015029144A BR 112015029144 A BR112015029144 A BR 112015029144A BR 112015029144 A2 BR112015029144 A2 BR 112015029144A2
Authority
BR
Brazil
Prior art keywords
radiotherapy
gel formulations
ray contrast
administered
contrast composition
Prior art date
Application number
BR112015029144A
Other languages
English (en)
Inventor
Albrechtsen Morten
Irming Jølck Rasmus
Lars Andresen Thomas
Original Assignee
Univ Danmarks Tekniske
Nanovi Radiotherapy Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Danmarks Tekniske, Nanovi Radiotherapy Aps filed Critical Univ Danmarks Tekniske
Publication of BR112015029144A2 publication Critical patent/BR112015029144A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48Diagnostic techniques
    • A61B6/481Diagnostic techniques involving the use of contrast agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0442Polymeric X-ray contrast-enhancing agent comprising a halogenated group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452Solutions, e.g. for injection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0457Semi-solid forms, ointments, gels, hydrogels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476Particles, beads, capsules, spheres
    • A61K49/0485Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo "formulações de gel para guiar radioterapia" a presente invenção descreve uma composição de contraste de raios x para administração local, sendo que a composição de contraste de raios x demonstra propriedades de contraste e em que ao menos 60% de uma quantidade administra-da de dita composição de contraste de raios x permanecem mais de 24 horas a 10 cm de um ponto de injeção quando a composição de contraste de raios x é adminis-trada no corpo humano ou animal.
BR112015029144A 2013-05-24 2014-05-23 formulações de gel para guiar radioterapia BR112015029144A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350637 2013-05-24
PCT/EP2014/060673 WO2014187962A1 (en) 2013-05-24 2014-05-23 Gel formulations for guiding radiotherapy

Publications (1)

Publication Number Publication Date
BR112015029144A2 true BR112015029144A2 (pt) 2017-07-25

Family

ID=50819731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029144A BR112015029144A2 (pt) 2013-05-24 2014-05-23 formulações de gel para guiar radioterapia

Country Status (15)

Country Link
US (2) US10561746B2 (pt)
EP (1) EP3003397B1 (pt)
JP (1) JP6537498B2 (pt)
KR (1) KR102242406B1 (pt)
CN (1) CN105407927B (pt)
AU (1) AU2014270358B2 (pt)
BR (1) BR112015029144A2 (pt)
CA (1) CA2913100C (pt)
DK (1) DK3003397T3 (pt)
ES (1) ES2828752T3 (pt)
HK (1) HK1223545A1 (pt)
IL (1) IL242676B (pt)
MX (1) MX2015016155A (pt)
RU (1) RU2703303C2 (pt)
WO (1) WO2014187962A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703303C2 (ru) 2013-05-24 2019-10-16 Данмаркс Текниске Университет Состав геля для лучевой терапии под визуальным контролем
WO2016079331A1 (en) * 2014-11-21 2016-05-26 Technical University Of Denmark Gel formulations for enhancing the effect of radiotherapy
CN104645356B (zh) * 2015-01-30 2018-11-13 复旦大学 一类x射线显影的热致水凝胶及其制备方法
US11058780B2 (en) * 2016-05-20 2021-07-13 Technical University Of Denmark Palpable marker composition
WO2018215595A1 (en) 2017-05-24 2018-11-29 Technical University Of Denmark Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility
US11124630B2 (en) * 2017-06-04 2021-09-21 Technion Research & Development Foundation Limited Inverse-freezing compositions and use thereof
IL257226B2 (en) * 2018-01-29 2023-04-01 Technion Res & Development Found Ltd Compounds characterized by an inverse freezing property and their uses
WO2019243419A1 (en) * 2018-06-19 2019-12-26 Danmarks Tekniske Universitet Brachygel for treatment of cancer and/or for guidance of surgery
EP3810207A1 (en) * 2018-06-19 2021-04-28 Danmarks Tekniske Universitet Solution comprising fluorescent dye as fiducial marker
EP3962496A4 (en) * 2019-05-03 2023-01-11 Palette Life Sciences, Inc. IMPROVED FABRIC SPACERS
US20220339285A1 (en) * 2019-06-12 2022-10-27 Technical University Of Denmark Dissacharide formulations for controlled drug release
KR102323957B1 (ko) * 2019-07-26 2021-11-08 경북대학교 산학협력단 모든 자기공명영상촬영 및 전산화단층촬영 용 영상 마커 및 이의 제조 방법
EP4061438A4 (en) * 2019-11-20 2024-01-10 The Regents of the University of California COMPOSITION OF LIQUID EMBOLIC MATERIAL
CN111228215A (zh) * 2020-03-09 2020-06-05 王岩松 一种自组装可成像丝素蛋白水凝胶的制备方法
CN111632142B (zh) * 2020-06-24 2022-08-23 南方科技大学 一种基于x射线响应的药物释放系统及其制备方法和应用
CN112279945B (zh) * 2020-10-13 2022-05-27 青岛科技大学 一种感温变色水凝胶型智能视窗及其制备方法、产品与应用
CN114652862A (zh) * 2020-12-23 2022-06-24 成都纽瑞特医疗科技股份有限公司 一种放射性树脂微球注射剂及制备方法和用途
WO2022147009A1 (en) * 2020-12-29 2022-07-07 Precise-Therapeutics Llc Compositions and associated methods for sustained-release of radioactive agents and their applications
US11672875B2 (en) * 2021-03-17 2023-06-13 Saint Louis University Nanoparticle-alginate gels for X-ray imaging of the vasculature
CN115282127B (zh) * 2022-04-21 2023-08-29 广州医科大学附属第二医院 壳聚糖海藻酸钙纳米粒微球及其制备方法
WO2023245093A1 (en) * 2022-06-16 2023-12-21 Theragenics Corporation Photocurable compositions and methods for delivering radiation to a subject
CN115678048B (zh) * 2022-11-27 2024-05-31 福州大学 一种可促进创面愈合并减少疤痕形成的可注射复合水凝胶及其制备方法和应用
CN116251201B (zh) * 2023-04-03 2024-04-05 无锡市第二人民医院 抗类风湿性关节炎的自组装水凝胶及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE403255B (sv) 1972-09-19 1978-08-07 Pharmacia Ab Rontgenkontrastmedel i vilket ett rontgenkontrastgivande emne utgores av en polymer i vilken ingar jodsubstituerade aromatiska grupper
US5562099A (en) 1990-10-05 1996-10-08 Massachusetts Institute Of Technology Polymeric microparticles containing agents for imaging
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
CA2222567C (en) 1995-06-07 2002-01-29 Southern Biosystems, Inc. High viscosity liquid controlled biologically active delivery system
DE69920425T2 (de) 1998-04-09 2005-09-29 Amersham Health As Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
SE522098C2 (sv) 2001-12-20 2004-01-13 Bone Support Ab Ett nytt benmineralsubstitut
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
JP3755880B2 (ja) * 2003-06-11 2006-03-15 日本航空電子工業株式会社 コネクタ
US7790141B2 (en) 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
EP2415484B1 (en) * 2004-09-17 2014-06-18 Durect Corporation Sustained local anesthetic composition containing SAIB
EP1890739A1 (en) * 2005-05-12 2008-02-27 Angiotech International Ag Compositions and methods for treating diverticular disease
CN101309713A (zh) * 2005-11-17 2008-11-19 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
US20090026345A1 (en) * 2007-07-24 2009-01-29 Tracy Mark S Electronic device shock-absorbing mounting system
US9295736B2 (en) 2007-09-24 2016-03-29 Bar Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
EP2229147A2 (en) 2007-12-03 2010-09-22 The Johns Hopkins University Methods of synthesis and use of chemospheres
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CA3042067C (en) 2009-12-15 2022-10-18 Incept, Llc Implants and biodegradable fiducial markers
AU2011278308B2 (en) * 2010-07-16 2014-09-04 Technical University Of Denmark Nanoparticle-guided radiotherapy
US20120039814A1 (en) 2010-08-13 2012-02-16 Sample Jennifer L Topical Compositions and Methods of Detection and Treatment
US20120065614A1 (en) 2010-09-10 2012-03-15 University Of North Texas Polyionic transitional metal phosphorescent complex/polymer hybrid systems for bioimaging and sensing applications
WO2013076305A1 (en) * 2011-11-25 2013-05-30 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
RU2703303C2 (ru) 2013-05-24 2019-10-16 Данмаркс Текниске Университет Состав геля для лучевой терапии под визуальным контролем

Also Published As

Publication number Publication date
AU2014270358A1 (en) 2015-12-03
CN105407927A (zh) 2016-03-16
CN105407927B (zh) 2020-03-20
CA2913100C (en) 2021-10-26
WO2014187962A1 (en) 2014-11-27
CA2913100A1 (en) 2014-11-27
RU2703303C2 (ru) 2019-10-16
US10561746B2 (en) 2020-02-18
US20200197541A1 (en) 2020-06-25
DK3003397T3 (da) 2020-11-16
EP3003397B1 (en) 2020-08-19
JP6537498B2 (ja) 2019-07-03
KR102242406B1 (ko) 2021-04-21
RU2015154681A (ru) 2017-06-30
HK1223545A1 (zh) 2017-08-04
AU2014270358B2 (en) 2019-01-17
NZ714077A (en) 2020-12-18
JP2016519154A (ja) 2016-06-30
MX2015016155A (es) 2016-08-19
US20160089454A1 (en) 2016-03-31
EP3003397A1 (en) 2016-04-13
ES2828752T3 (es) 2021-05-27
KR20160032008A (ko) 2016-03-23
IL242676B (en) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112015020302A2 (pt) derivado de pirazol
BR112015021352A2 (pt) composições antimicrobianas
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
NZ749217A (en) Androgen receptor modulator and uses thereof
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112013004889A2 (pt) composição de proteção de superfície sem fluoropolímero
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112018014027A2 (pt) composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112016013194A2 (pt) Composições de higiene oral compreendendo carbonato de cálcio e sílica
BR112016027435A2 (pt) formulação inovadora de meloxicam
BR112013028786A2 (pt) método e composição de tratamento de sementes
BR112018075221A2 (pt) micropartículas compreendendo um composto contendo enxofre
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112015032284A2 (pt) dispositivo médico compreendendo colágeno-vi

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements